Endocannabinoid Receptors Gene Expression in Morbidly Obese Women with Nonalcoholic Fatty Liver Disease

Table 1

Characteristics of study cohort classified according to the liver pathology.

	Morbidly Obese (𝑛=72)
	NL; (𝑛=16)	SS; (𝑛=28)	NASH; (𝑛=28)
	Mean ± SD	Mean ± SD	Mean ± SD
Age (years)	44.0 ± 3.2	47.4 ± 1.5	45.9 ± 1.4
Weight (kg)	121.0 ± 12.1	121.8 ± 16.3	123.8 ± 14.3
WC (cm)	129.5 ± 6.4	132.1 ± 10.7	135.1 ± 9.9
BMI (kg/m^2)	48.6 ± 2.6	48.1 ± 7.8	47.5 ± 5.4
Glucose (mg/dL)	101.8 ± 18.9	125.4 ± 38.2	119.0 ± 30.0
Insulin (mUI/L)	11.4 ± 3.1	21.2 ± 11.5	23.1 ± 28.1
HbA1c (%)	4.3 ± 0.3	5.9 ± 1.7	5.8 ± 1.7
HOMA2-IR	1.5 ± 0.5	2.9 ± 1.4	3.0 ± 3.4
HDL-C (mg/dL)	43.6 ± 7.6	39.3 ± 9.5	41.5 ± 9.0
LDL-C (mg/dL)	102.0 ± 31.7	104.7 ± 24.6	102.5 ± 32.6
Triglycerides (mg/dL)	144.4 ± 51.9	178.4 ± 68.5	183.1 ± 86.6
AST (U/L)	25.8 ± 8.5	43.7 ± 34.4*	44.9 ± 29.3*
ALT (U/L)	25.4 ± 10.5	45.6 ± 31.6*	46.3 ± 28.3*
GGT (U/L)	18.3 ± 13.8	30.6 ± 22.2	36.1 ± 31.7
ALP (U/L)	58.2 ± 12.6	66.3 ± 16.0	71.9 ± 15.2*
Adipocytokine levels
Adiponectin (µg/mL)	10.1 ± 2.0	6.8 ± 3.5	6.7 ± 2.4
IL6 (pg/mL)	2.1 ± 0.6	2.9 ± 2.5	3.3 ± 2.0
Resistin (ng/mL)	5.1 ± 2.1	4.6 ± 2.0	4.5 ± 1.6
TNFRII (ng/mL)	4.2 ± 1.4	5.5 ± 2.5	5.6 ± 1.7
CRP (mg/dL)	1.0 ± 0.8	0.9 ± 0.7	1.1 ± 0.7

NL: morbidly obese subjects with normal liver; SS: morbidly obese subjects with simple steatosis; NASH: morbidly obese subjects with steatohepatitis; ALT: alanine aminotransferase; ALP: alkaline phosphatase; AST: aspartate aminotransferase; BMI: body mass index; CRP: C-reactive protein; GGT: gamma-glutamyltransferase; HbA1c: glycosylated haemoglobin; HDL-C: high density lipoprotein; HOMA2-IR: homeostatic model assessment 2-insulin resistance; IL6: interleukin 6; LDL-C: low density lipoprotein; TNFRII: tumour necrosis factor receptor II; WC: waist circumference. ∗indicates significant differences respect NL group (𝑃<0.05).